[Possibilities and limitations of immunosuppressive therapy for glomerulonephritis].
Possibility and necessity of the immunosuppressive treatment is considerably determined by the underlying pathologo-anatomical substrate. The uncertainty concerning the chances of the success of such a therapy for the individual patient at least still at present allows a latitude of estimation. From this results the demand for a particularly intensive conscience of the responsibility taken on by us in finding the decision.
D000208:Acute Disease; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000276:immunology; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D002699:Chlorambucil; D003609:Dactinomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate
Möglichkeiten und Grenzen immunsuppressiver Therapie der Glomerulonephritis.